Help researchers and clinicians better understand how patients with myositis and other autoimmune conditions feel about COVID-19/the novel coronavirus.
Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis VideoMyositis Support, , Featured, Inclusion Body Myositis (IBM)
The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
Identification of Predictors for Interstitial Lung Disease in Myositis Patients: A Systematic ReviewMyositis Support, , Featured, Myositis, News
Interstitial lung disease (ILD) is a well-recognized complication in the spectrum of diseases known as the idiopathic inflammatory myopathies...
The first step when approaching a patient with muscle weakness – Differential diagnosis of idiopathic inflammatory myopathies in adultsMyositis Support, , Featured, Myositis
Information on the differential diagnosis of adults with muscle weakness. Differential diagnosis is the process of distinguishing a specific...
The information collected by ultrasound elastography (USE), such as structural changes of muscle, is thought to make it useful for...
Choose your language
- Myositis Awareness, September 2020
- Myositis Empower Walk, Join us 9/19/20
- The Grieving Project
- Explore Myositis
- Financial Assistance Program
- #ItsMyTurn: Becoming a Plasma Donor Hero
- Myositis Clinical Trials
- Myositis Webinars
- Upcoming Events
- Donate today!